Clinical Trial

A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

This is a multicenter, randomized, study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. The primary objectives are to evaluate the safety and efficacy of the vaccine compared to placebo.

Information

Principal Investigator Dynio Honrubia, MD
Co-PI
Sponsor National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC)
Type of Trial Interventional